Is Tepezza used to treat Graves disease?
Tepezza (teprotumumab-trbw) is a prescription medicine used to treat Thyroid Eye Disease (TED). TED often occurs in people living with Graves’ disease (too much thyroid hormone). TED and Graves’ disease are both autoimmune disorders, but are different conditions and are treated differently. With an autoimmune disorder, your immune system mistakenly attacks your own healthy tissues.
Other names for thyroid eye disease (TED) include:
- Graves’ orbitopathy
- Graves’ ophthalmopathy
- Graves’ eye disease
- Graves’ disease eyes
- Thyroid-associated ophthalmopathy
TED
Thyroid Eye Disease (TED) is a rare, serious and sight-threatening autoimmune disease. It is a progressive disease and can get worse over time. You can develop TED without having Graves’ disease. With TED, the muscle and fat behind the eye is attacked and becomes inflamed and red, leading to symptoms. Specialists recommend getting a diagnosis and treatment as early as possible.
The symptoms of TED may include:
- eye bulging
- double vision
- dry, gritty eyes
- watery eyes
- blurry vision
- light sensitivity
- eye pain or pressure
- misaligned eyes
- itchy eyes
- swollen, puffy, red eyes or eyelids
- eyelids are pulled back
- color vision loss
- blindness (rare)
Graves' disease
Graves’ disease is caused by overproduction of thyroid hormones (hyperthyroidism). In Graves’ disease the thyroid is attacked and leads to an overproduction of thyroid hormones. The thyroid gland sits at the base of your neck. Up to 50% of people diagnosed with Graves’ disease will develop TED.
Graves’ disease is often treated with antithyroid medicines like methimazole (Tapazole) or propylthiouracil, beta-blockers, radioactive iodine therapy or surgery. Endocrinologists are the specialists that usually manage Graves’ disease.
The symptoms of Graves’ disease include:
- eye bulging
- anxiety
- irritability
- tremor in the hand or fingers
- increased sweating
- weight loss (despite normal eating)
- enlarged thyroid gland (goiter)
- changes in a menstrual cycles
- erectile dysfunction
- decreased sex drive
- frequent bowel movements
- tiredness
- trouble sleeping
- thickened red skin, often on the feet or front of legs
- irregular heartbeats. Not everyone who has Graves’ disease gets TED.
Related questions
- What are monoclonal antibodies?
- How does Tepezza work, what's the mechanism of action?
- Tepezza before and after, what should I expect?
How well does Tepezza work?
Tepezza can help to reduce the eye bulging, double vision, and eye pain, redness and swelling that may occur with TED. Currently, Tepezza is the only FDA-approved treatment for TED.
- In studies, Tepezza effectiveness was based on the OPTIC study which found a significant improvement in eye bulging (82.9%) compared to placebo (9.5%). Secondary endpoints were also met, including double-vision improvements.
- It may cause side effects such as nausea, diarrhea, hair loss, menstrual changes, fatigue, hearing impairment, dry skin, taste changes, muscle spasms and increased blood sugar levels. More serious side effects can include: infusion reactions, high blood sugar and worsening of inflammatory bowel disease.
Tepezza (teprotumumab) is the first medicine approved for the treatment of Thyroid Eye Disease (TED). Tepezza is given by your healthcare provider as an intravenous (IV) infusion into a vein once every three weeks for a total of eight infusions. Ophthalmologists are the specialists that typically treat TED.
Other treatments for TED include artificial tears, corticosteroids, prism glasses, or surgery.
Related: How does Tepezza work, what's the mechanism of action?
This is not all the information you need to know about Tepezza (teprotumumab-trbw) for safe and effective use and does not take the place of your doctor’s directions. Review the full product information and discuss this information and any questions you have with your doctor or other health care provider.
References
- Thyroid Eye Disease vs. Graves’ Disease. Horizon. Accessed June 7, 2022 at https://www.thyroideyes.com/about-thyroid-eye-disease/ted-vs-graves
- Thyroid Eye Disease vs Graves’ Disease. Accessed June 7, 2022 at https://www.tepezza.com/thyroid-eye-disease/
- Tepezza (teprotumumab) product information. Lake Forest, IL. Horizon Therapeutics USA, Inc. Accessed June 7, 2022 at https://www.hzndocs.com/TEPEZZA-Prescribing-Information.pdf
Read next
How long does it take Tepezza to work?
In studies with Tepezza (teprotumumab-trbw), some patients began to see less eye bulging and double vision by 6 weeks (after the first 2 treatments). By 24 weeks, 8 out of 10 (80%) of patients saw less eye bulging compared to 10 of 100 (10%) of patients taking a placebo. Continue reading
How long does Tepezza stay in your system?
Tepezza stays in your system approximately 100 days after the last dose. This is calculated by looking at the average half-life of Tepezza which is 20 days. The half-life is the time it takes for 50% of a medicine to be eliminated from the body. Research has shown that it takes 4 to 5 half-lives for a medicine to be fully cleared from the body which calculates out to 80 to 100 days or 11 to 14 weeks for Tepezza. Continue reading
Is Tepezza a chemotherapy drug?
No, Tepezza is not used for chemotherapy or to treat any form of cancer. Tepezza is used to treat Thyroid Eye Disease, an autoimmune disease. An autoimmune disease is a condition that causes your body's immune system to mistakenly attack healthy cells in your body instead of foreign substances. Continue reading
Related medical questions
- Tepezza and COVID vaccine, what should I know?
- Can Tepezza treat eye bulging and double vision?
- How is Tepezza injected and administered?
- Does Tepezza cause hearing loss?
- How does propylthiouracil work?
Drug information
- Tepezza Information for Consumers
- Tepezza prescribing info & package insert (for Health Professionals)
- Side Effects of Tepezza (detailed)
- Tepezza user reviews (5)
Related support groups
- Tepezza (11 questions, 8 members)
- Thyroid Eye Disease (8 questions, 3 members)
- Graves' Disease (3 questions, 39 members)
- Graves' Ophthalmopathy (2 questions, 11 members)